Anavex Life Sciences Corp (AVXL)

[drv17]

Dr. Missling's answer to funding.
TWST: Do you have the financing you need to get through the development of ANAVEX 2-73 at this current stage?

Dr. Missling: Yes, we believe that sufficient financing in place and also because we are working with several foundations on specific diseases like the Michael J. Fox Foundation that has supported us very strongly for exploring ANAVEX 2-73 in a pre-clinical study of Parkinson’s disease, for which positive data was recently reported on September 22nd. And we also received support from the Rettsyndrome.org foundation, which also supported exploring ANAVEX 2-73 in a pre-clinical study in Rett syndrome, a rare disease for which Anavex received FDA orphan designation this year. We might continue these collaborations if the data continues to be promising.

Filed with SEC 10/21/16 This is superb Media coverage,
The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Managers


EX-99.1 2 s104371_ex99-1.htm EXHIBIT 99-1

Exhibit 99.1

Christopher U. Missling, MS, PhD, MBA, President and CEO of Anavex Life Sciences Corp.